Literature DB >> 31920105

A Phase II study of preoperative chemotherapy with docetaxel, oxaliplatin and S-1 in gastric cancer with extensive lymph node metastasis (JCOG1704).

Yuya Sato1, Yukinori Kurokawa2, Yuichiro Doki2, Junki Mizusawa1, Kiyo Tanaka1, Hiroshi Katayama1, Narikazu Boku3, Takaki Yoshikawa4, Masanori Terashima5.   

Abstract

Background: Although surgical resection is necessary to cure the locally advanced gastric cancer, it is sometimes difficult for extensive nodal metastasis such as para-aortic nodal disease or bulky nodal metastasis around the major gastric branched arteries. We had conducted several Phase II studies and clarified preoperative chemotherapy with doublet regimen followed by surgery markedly improved the survival for this disease. Recently, preoperative chemotherapy with docetaxel, oxaliplatin and S-1 (DOS) showed promising efficacy and acceptable feasibility for resectable advanced gastric cancer. Aim: To describe the design and rationale for the multi-institutional, single-arm, Phase II trial of systemic chemotherapy with DOS followed by surgery in advanced gastric cancer with extensive lymph node metastasis (JCOG1704). If efficacy and safety of DOS can be shown, we will conduct a Phase III trial comparing preoperative DOS and current standard cisplatin and S-1. Trial registration: jRCTs031180028.

Entities:  

Keywords:  DOS; bulky lymph node metastasis; extensive lymph node metastasis; gastric cancer; para-aortic lymph node dissection; para-aortic lymph node metastases; preoperative chemotherapy

Year:  2020        PMID: 31920105     DOI: 10.2217/fon-2019-0528

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  5 in total

Review 1.  Current status of conversion surgery for stage IV gastric cancer.

Authors:  Jun Kinoshita; Takahisa Yamaguchi; Hideki Moriyama; Sachio Fushida
Journal:  Surg Today       Date:  2021-01-23       Impact factor: 2.549

2.  Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study.

Authors:  Shunji Endo; Tetsuji Terazawa; Masahiro Goto; Ryo Tanaka; Takeshi Kato; Kazumasa Fujitani; Hisato Kawakami; Daisuke Sakai; Yukinori Kurokawa; Toshimasa Tsujinaka; Toshio Shimokawa; Taroh Satoh
Journal:  BMC Cancer       Date:  2022-07-23       Impact factor: 4.638

Review 3.  History and emerging trends in chemotherapy for gastric cancer.

Authors:  Keishi Yamashita; Kei Hosoda; Masahiro Niihara; Naoki Hiki
Journal:  Ann Gastroenterol Surg       Date:  2021-02-01

4.  Impact of preoperative endoscopy for predicting treatment response and prognosis in patients with gastric cancer after neoadjuvant chemotherapy.

Authors:  Yoshiaki Shoji; Souya Nunobe; Naoki Nishie; Shusuke Yagi; Rie Makuuchi; Satoshi Ida; Koshi Kumagai; Manabu Ohashi; Akiyoshi Ishiyama; Toshiyuki Yoshio; Toshiaki Hirasawa; Junko Fujisaki; Takeshi Sano
Journal:  Endosc Int Open       Date:  2022-01-14

Review 5.  Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature.

Authors:  Hideaki Shimada; Takeo Fukagawa; Yoshio Haga; Shin-Ichi Okazumi; Koji Oba
Journal:  Ann Gastroenterol Surg       Date:  2021-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.